Acadia Pharmaceuticals Reports First Quarter 2023 Financial

- 1Q23 NUPLAZID® net sales of $118.5 million


- Announced the U.S. FDA Approval of DAYBUE™ for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older on... | May 8, 2023

Related Keywords

, Steve Davis , Linkedin , Acadia Pharmaceuticals Inc , Company Operational , Twitter , Exchange Commission , Nasdaq , Drug Administration , Acadia Pharmaceuticals , Chief Executive , Rare Pediatric Disease Priority Review , Stoke Therapeutics , Private Securities Litigation Reform Act , Rett Syndrome Like , Natl Acad Sci United , Pharmaceuticals Inc , Months Ended March , Acadia Pharmaceuticals Inc Stock Exchange , News , Information , Press Release , 1q23 , Pet , Sales , F , Nnounced , The , Fda , Approval , Or , Treatment , Brett , Yndrome , N , Adult , End , Pediatric , Patients , Two , Tears , Age , Lder Acad Us0042251084 ,